ArticleTranslational pediatrics2025
Effect of myeloid-derived suppressor cells on retinal epithelial cells in retinopathy of prematurity model.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retinopathy of prematurity (ROP) is a proliferative vascular disease with a high incidence rate. Myeloid-derived suppressor cells (MDSCs) are a type of stem cell that possesses remarkable regenerative and reparative capabilities. However, the role of MDSCs as a stem cell therapy in the treatment of ROP remains unclear. Therefore, this study aimed to explore the effects of MDSC therapy on the expression of glial fibrillary acidic protein (GFAP) and vascular endothelial growth factor (VEGF) in a model of ROP, thereby preliminarily assessing the therapeutic potential of MDSCs in ROP. Methods: Bone marrow-derived MDSCs were obtained from an 8-week-old male C57BL/6J mouse, which served as the cell donor. The cells were divided into the model group, which was established by culturing hydrogen peroxide (H Results: The expression levels of GFAP and VEGF in the model + MDSCs group were significantly lower compared to the model group. In the model + MDSCs group, GFAP and VEGF expression levels were significantly reduced. Immunofluorescence analysis revealed a significant increase in GFAP and VEGF expression in the model + medium group. In contrast, the expression levels of GFAP and VEGF in the model + MDSCs group were markedly decreased. Conclusions: Co-culturing with MDSCs significantly reduces the expression levels of GFAP and VEGF in the model group, thereby inhibiting pathological neovascularization, inflammatory responses, and immune-mediated damage. This intervention subsequently improves the pathological processes associated with ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.